Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who previously took part in the MNPR-101-D001 study.
- Women who could become pregnant must have a negative pregnancy blood test at the screening visit, and a negative pregnancy urine test on the first day of treatment if screening took place more than 7 days earlier.
- Both men and women must agree to use highly effective birth control during the treatment period and for up to 3 months after the last dose, if there is any possibility of pregnancy.
- Women who are currently breastfeeding must agree to stop breastfeeding before receiving the study drug, and must not breastfeed for 3 months after the last dose.
Who may not be able to join:
- People who received chemotherapy, radiation therapy (other than a short course of palliative radiation), or immunotherapy within 14 days before receiving the study drug.
- People who are still experiencing significant side effects (graded as severe or higher) from a previous cancer treatment.
- People who received any radioactive drug treatment or other experimental treatment within 4 weeks or 5 half-lives (whichever is longer) before the first dose, except for a specific imaging agent used in the earlier study (MNPR-101-DFO*-89Zr).
- People whose blood test results at screening show poor bone marrow function, such as low platelet counts, low white blood cell counts, or low haemoglobin levels (including those who have received a red blood cell transfusion in the past 4 weeks).
- People whose blood test results show that the liver is not working well enough, based on specific enzyme and bilirubin level thresholds (confirm with trial site).
- People whose kidney function is too low, based on a specific kidney function calculation (confirm with trial site).
- People who experienced a serious blood-related or liver-related side effect during the earlier MNPR-101-D001 study that was linked to the study treatment.
- People whose earlier study results show that the radiation dose their organs would receive is too high to be considered safe, as assessed by the study sponsor.
- People with other serious non-cancer illnesses affecting the kidneys, liver, or blood that could interfere with the study, as judged by the study doctor.
- People who have cognitive difficulties or other conditions that may prevent them from giving informed consent or following the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 847-794-8435
Australian sites
03 9454 5800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of fractionated MNPR-101-PCTA-177Lu dosing
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.